Biotechnology - Biotechnology, Zaltrap

Filter

Current filters:

BiotechnologyZaltrap

Popular Filters

Approved cancer drug potentially could help treat diabetes, Stanford researchers find

16-09-2013

A pair of studies by researchers at the Stanford University School of Medicine has identified a molecular…

afliberceptBayerBiotechnologyDiabetesEyleaOncologyPharmaceuticalRegeneronResearchSanofiZaltrap

Regeneron posts strong growth for 2012, beating analysts' estimates

15-02-2013

US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) yesterday announced that total revenues were…

BiotechnologyEyleaFinancialOncologyOphthalmicsRegeneronZaltrap

Positive CHMP recommendations for Sanofi and Novartis, but not for Celgene

19-11-2012

There was a batch of good news for two pharma companies and a negative opinion for one last Friday coming…

BexseroBiotechnologyCelgeneDiabetesEuropeIstodaxLyxumiaNovartisOncologyPharmaceuticalRegulationSanofiVaccinesZaltrap

Bayer's Stivarga races to FDA approval on the heels of Zaltrap

07-10-2012

The earlier than expected US Food and Drug Administration approval of German drug major Bayer's (BAYN:…

BayerBiotechnologyMarkets & MarketingNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalregorafenibRegulationSanofiStivargaZaltrap

Sanofi and Regeneron mCRC drug Zaltrap misses goals but gets FDA priority

10-04-2012

The US Food and Drug Administration has granted priority review of the Biologics License Application…

BiotechnologyNorth AmericaPharmaceuticalRegeneronRegulationResearchSanofiZaltrap

Back to top